Literature DB >> 6350816

Hemodynamic factors in the genesis of diabetic microangiopathy.

H H Parving, G C Viberti, H Keen, J S Christiansen, N A Lassen.   

Abstract

There are many candidate mechanisms to explain the phenomenon of delayed microvascular disease in the diabetic. All may play some part in determining the genesis, the evolution or the ultimate degree and form of the angiopathy. General metabolic and humoral factors may provide the pathogenetic background against which special local conditions, e.g., in the retina or renal cortex, will determine the morphology of the angiopathy and its functional and structural consequences. Some of the processes occurring in the diabetic person may, however, be of major importance in initiating and maintaining conditions for the evolution of microvascular disease. The hemodynamic changes and the vascular responses to them that we have described are, we suggest, very likely to be an important component of this sort. Unlike the later structural changes, these hemodynamic phenomena are to be found very early in the diabetic state. Of most clinical importance, perhaps, is that they appear, with the achievement of adequate metabolic correction, to be reversible.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6350816     DOI: 10.1016/0026-0495(83)90210-x

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  54 in total

1.  Plasma lipoproteins and renal function during simvastatin treatment in diabetic nephropathy.

Authors:  E Hommel; P Andersen; M A Gall; F Nielsen; B Jensen; P Rossing; J Dyerberg; H H Parving
Journal:  Diabetologia       Date:  1992-05       Impact factor: 10.122

2.  Effect of captopril on kidney function in insulin-dependent diabetic patients with nephropathy.

Authors:  E Hommel; H H Parving; E Mathiesen; B Edsberg; M Damkjaer Nielsen; J Giese
Journal:  Br Med J (Clin Res Ed)       Date:  1986-08-23

3.  Glucose-induced microvascular functional changes in nondiabetic rats are stereospecific and are prevented by an aldose reductase inhibitor.

Authors:  J R Williamson; E Ostrow; D Eades; K Chang; W Allison; C Kilo; W R Sherman
Journal:  J Clin Invest       Date:  1990-04       Impact factor: 14.808

4.  Effects of intensified insulin treatment on retinal vessels in diabetic patients.

Authors:  O Brinchmann-Hansen; K Dahl-Jørgensen; K F Hanssen; L Sandvik
Journal:  Br J Ophthalmol       Date:  1988-09       Impact factor: 4.638

5.  Exercise as a provocative test in early renal disease in type 1 (insulin-dependent) diabetes: albuminuric, systemic and renal haemodynamic responses.

Authors:  B Feldt-Rasmussen; L Baker; T Deckert
Journal:  Diabetologia       Date:  1985-07       Impact factor: 10.122

6.  Strict control of glycaemia: effects on blood flow in the large retinal vessels and in the macular microcirculation.

Authors:  J E Grunwald; C E Riva; B L Petrig; A J Brucker; S S Schwartz; S N Braunstein; J DuPont; S Grunwald
Journal:  Br J Ophthalmol       Date:  1995-08       Impact factor: 4.638

7.  The glomerular hyperfiltration of diabetes is not associated with elevated plasma levels of glucagon and growth hormone.

Authors:  M J Wiseman; S Redmond; F House; H Keen; G C Viberti
Journal:  Diabetologia       Date:  1985-10       Impact factor: 10.122

Review 8.  New insights into molecular mechanisms of diabetic kidney disease.

Authors:  Shawn S Badal; Farhad R Danesh
Journal:  Am J Kidney Dis       Date:  2014-02       Impact factor: 8.860

9.  Impaired blood flow and arterio-venous shunting in human diabetic neuropathy: a novel technique of nerve photography and fluorescein angiography.

Authors:  S Tesfaye; N Harris; J J Jakubowski; C Mody; R M Wilson; I G Rennie; J D Ward
Journal:  Diabetologia       Date:  1993-12       Impact factor: 10.122

10.  Increased transcapillary escape rate of albumin in type 1 (insulin-dependent) diabetic patients with microalbuminuria.

Authors:  B Feldt-Rasmussen
Journal:  Diabetologia       Date:  1986-05       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.